The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing commitment to enhancing therapeutic options for HER2-positive metastatic breast ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE: AZN) have released detailed Phase III results that could help position their ...

Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “Bringing ENHERTU earlier in the treatment of HER2-positive metastatic breast cancer may represent an ...

AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ...

“The superior overall survival demonstrated in DESTINY-Gastric04 confirms that ENHERTU could become the global standard of care in the second-line metastatic setting of HER2 positive gastric ...

Tumors with low- and ultra-low levels of a protein called HER2 are treatable with Enhertu, but harder to identify. New ...